Suppr超能文献

上尿路疾病:我们如今所了解的情况及未满足的需求。

Upper urinary tract disease: what we know today and unmet needs.

作者信息

Mathieu Romain, Bensalah Karim, Lucca Ilaria, Mbeutcha Aurélie, Rouprêt Morgan, Shariat Shahrokh F

机构信息

1 Department of Urology, Rennes University Hospital, Rennes, France ; 2 Department of Urology, General Hospital, Medical University Vienna, Vienna, Austria ; 3 Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland ; 4 Academic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France ; 5 Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA ; 6 Department of Urology, Weill Cornell Medical College, New York, USA.

出版信息

Transl Androl Urol. 2015 Jun;4(3):261-72. doi: 10.3978/j.issn.2223-4683.2015.05.01.

Abstract

PURPOSE

Upper tract urothelial carcinoma (UTUC) is a rare and poorly investigated disease. Intense collaborative efforts have increased our knowledge and improved the management of the disease. The objective of this review was to discuss recent advances and unmet needs in UTUC.

METHODS

A non-systematic Medline/PubMed literature search was performed on UTUC using the terms "upper tract urothelial carcinoma" with different combinations of keywords. Original articles, reviews and editorials in English language were selected based on their clinical relevance.

RESULTS

UTUC is a disease with specific epidemiologic and risk factors different to urothelial carcinoma of the bladder (UCB). Similarly to UCB, smoking increases the risk of UTUC and worsens its prognosis, whereas aristolochic acid (AA) exposure and mismatch repair genes abnormality are UTUC specific risk factors. A growing understanding of biological pathways involved in the tumorigenesis of UTUC has led to the identification of promising prognostic/predictive biomarkers. Risk stratification of UTUC is difficult due to limitations in staging and grading. Modern imaging and endoscopy have improved clinical decision-making, and allowed kidney-sparing management and surveillance in favorable-risk tumors. In high-risk tumors, radical nephroureterectomy (RNU) remains the standard. Complete removal of the intramural ureter is necessary with inferiority of endoscopic management. Post-RNU intravesical instillation has been shown to decrease bladder cancer recurrence rates. While the role of neoadjuvant cisplatin based combination chemotherapy and lymphadenectomy are not clearly established, the body of evidence suggests a survival benefit to these. There is currently no evidence for adjuvant chemotherapy (AC) in UTUC.

CONCLUSIONS

Despite growing interest and understanding of UTUC, its management remains challenging, requiring further high quality multicenter collaborations. Accurate risk estimation is necessary to avoid unnecessary RNUs while advances in technology are still required for optimal kidney-sparing approaches.

摘要

目的

上尿路尿路上皮癌(UTUC)是一种罕见且研究较少的疾病。通过密集的合作努力,我们对该疾病的认识有所增加,其治疗管理也得到了改善。本综述的目的是讨论UTUC的最新进展和未满足的需求。

方法

使用“上尿路尿路上皮癌”与不同关键词组合,对UTUC进行非系统性的Medline/PubMed文献检索。根据其临床相关性,选择英文的原始文章、综述和社论。

结果

UTUC是一种具有特定流行病学和危险因素的疾病,与膀胱尿路上皮癌(UCB)不同。与UCB类似,吸烟会增加UTUC的风险并使其预后恶化,而马兜铃酸(AA)暴露和错配修复基因异常是UTUC特有的危险因素。对UTUC肿瘤发生所涉及的生物学途径的认识不断加深,已导致发现了有前景的预后/预测生物标志物。由于分期和分级的局限性,UTUC的风险分层较为困难。现代影像学和内镜检查改善了临床决策,并允许对低风险肿瘤进行保留肾单位的管理和监测。在高风险肿瘤中,根治性肾输尿管切除术(RNU)仍然是标准治疗方法。完全切除壁内输尿管是必要的,内镜治疗效果较差。RNU术后膀胱内灌注已被证明可降低膀胱癌复发率。虽然基于顺铂的新辅助联合化疗和淋巴结清扫的作用尚未明确确立,但现有证据表明这些治疗对生存有益。目前尚无证据支持UTUC的辅助化疗(AC)。

结论

尽管对UTUC的兴趣和认识不断增加,但其管理仍然具有挑战性,需要进一步开展高质量的多中心合作。准确的风险评估对于避免不必要的RNU是必要的,而优化保留肾单位的方法仍需要技术上的进步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dde/4708228/e3cbf558f218/tau-04-03-261-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验